UCB Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
20
About the Report
About the Report
Summary
UCB Inc (UCB), a subsidiary of UCB SA, is a healthcare solutions provider that offers therapeutics. The company develops products with an emphasis on central nervous system and immunology therapeutic domains. Its products include cimzia, vimpat, keppra XR, neupro, tussionex pennkinetic, metadate CD, and others. UCB's products are used in the treatment of partial onset seizures, rheumatoid arthritis, attention deficit hyperactivity disorder and cough and upper respiratory symptoms associated with allergy or a cold. The company also conducts research and development to upgrade its products according to market requirements. It offers several health programs for patients, healthcare professionals and caregivers. The company operates through research triangle park located in North Carolina. UCB is headquartered in Smyrna, Georgia, the US.
UCB Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
UCB Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
UCB Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
UCB Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
UCB Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
UCB Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
UCB Inc, Medical Devices Deals, 2012 to YTD 2018 9
UCB Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
UCB Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Clementia Pharma Secures USD60 Million Venture Financing 11
Partnerships 13
Evotec Partners with UCB 13
Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 14
Licensing Agreements 15
UCB Exercises Option for Licensing Agreement with Oncodesign 15
UCB Enters Into Licensing Agreement With Medical Research Council Technology For Fibrosis Program 16
UCB Inc-Key Competitors 17
UCB Inc-Key Employees 18
UCB Inc-Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20
List of Figure
List of Figures
UCB Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
UCB Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
UCB Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
UCB Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
UCB Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
UCB Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
UCB Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
UCB Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
UCB Inc, Medical Devices Deals, 2012 to YTD 2018 9
List of Table
List of Tables
UCB Inc, Pharmaceuticals & Healthcare, Key Facts 2
UCB Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
UCB Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
UCB Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
UCB Inc, Deals By Therapy Area, 2012 to YTD 2018 8
UCB Inc, Medical Devices Deals, 2012 to YTD 2018 9
UCB Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Clementia Pharma Secures USD60 Million Venture Financing 11
Evotec Partners with UCB 13
Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 14
UCB Exercises Option for Licensing Agreement with Oncodesign 15
UCB Enters Into Licensing Agreement With Medical Research Council Technology For Fibrosis Program 16
UCB Inc, Key Competitors 17
UCB Inc, Key Employees 18
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.